Not all patients with CLL call for therapy. Despite all new advances, the iwCLL nevertheless endorses watchful observation for patients with asymptomatic ailment.86 This advice is based on at the very least two randomized trials evaluating observation to possibly chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,104